New Mexico native withdrawn from consideration to lead FDA
NEW MEXICO — The White House withdrew Heidi Overton, a Gallup native and University of New Mexico graduate, from consideration to lead the Food and Drug Administration.
The White House withdrew her nomination Tuesday, about three months after announcing it.
The Senate Health, Education, Labor, and Pensions Committee needed to sign off on Overton for her to move on to the full Senate. The committee consists of 12 Republicans and 11 Democrats, with Sen. Bill Cassidy, R-La., as the chairman.
If the Senate approved her with a simple majority, Overton would’ve led the FDA. She needed 50 senators plus the vice president or 51 senators voting yes. However, there were concerns about the votes – according to AP and lawmakers like Cassidy.
“Tonight, the White House abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members. I believe she would have had the votes to pass out of committee and pass the full Senate,” Cassidy said.
Overton was valedictorian of her Gallup High School class. At UNM, she earned a bachelor’s degree in health, medicine and human values in 2011 and graduated from the university’s medical school in 2015.
Overton earned a doctorate at Johns Hopkins University in 2022. Her nomination received praise from at least one prominent New Mexico leader.
“Dr. Overton’s nomination is an incredible accomplishment and a proud moment for New Mexico,” said House Republican Leader Gail Armstrong, R-Magdalena. “Her New Mexico roots and experience in medicine and public service have prepared her for this important role. On behalf of the House Republican Caucus, we congratulate Dr. Overton and wish her the very best through the confirmation process.”
Overton’s nomination came as the FDA reviews abortion medication policies, including an ongoing safety study of mifepristone. Former FDA commissioner Marty Makary resigned in May. Makary faced criticism from some Republicans, including U.S. Sen. Josh Hawley, over his agency’s handling of mifepristone.
The Atlantic described Overton as “one of the most powerful public health officials” in Trump’s second term as a domestic policy official who briefs him on health issues. She first rose to prominence as a White House fellow in 2019 and later joined the America First Policy Institute.
While she was with the AFPI, Overton described the 2022 U.S. Supreme Court decision to overturn Roe v. Wade as a “huge victory for life” and pushed for limits on access to abortion medications, including mifepristone and misoprostol.
The Democratic Party of New Mexico sharply criticized Overton’s nomination in a statement.
“Sadly, it appears that Trump selected an individual who will only continue his FDA’s agenda of restricting reproductive rights, promoting anti-vaccine policies, and increasing foodborne disease outbreaks. But we expect nothing less from Donald Trump, who has consistently made the least serious and most unqualified political appointments of any president in American history, than to appoint an unqualified, anti-abortion activist like Heidi Overton to such a critical position,” the party stated.
There is no word on who the White House will put forth instead as a pick for FDA commissioner.
The post New Mexico native withdrawn from consideration to lead FDA appeared first on KOB 4.
Ver nota original ↗
¿Querés un resumen rápido de esta noticia, hecho por nuestra IA?
